KR20230065309A - 저산소증-활성화된 dna 알킬화제 및 그의 의학적 용도 - Google Patents

저산소증-활성화된 dna 알킬화제 및 그의 의학적 용도 Download PDF

Info

Publication number
KR20230065309A
KR20230065309A KR1020237011813A KR20237011813A KR20230065309A KR 20230065309 A KR20230065309 A KR 20230065309A KR 1020237011813 A KR1020237011813 A KR 1020237011813A KR 20237011813 A KR20237011813 A KR 20237011813A KR 20230065309 A KR20230065309 A KR 20230065309A
Authority
KR
South Korea
Prior art keywords
compound
cancer
tumor
group
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237011813A
Other languages
English (en)
Korean (ko)
Inventor
안롱 리
지안신 두안
판잉 맹
샤오훙 차이
티안양 치
Original Assignee
아센타위츠 파마슈티컬즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아센타위츠 파마슈티컬즈 리미티드 filed Critical 아센타위츠 파마슈티컬즈 리미티드
Publication of KR20230065309A publication Critical patent/KR20230065309A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/564—Three-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
KR1020237011813A 2019-12-20 2021-06-23 저산소증-활성화된 dna 알킬화제 및 그의 의학적 용도 Pending KR20230065309A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201911324466 2019-12-20
CNPCT/CN2020/114519 2020-09-10
PCT/CN2020/114519 WO2021120717A1 (zh) 2019-12-20 2020-09-10 抗癌化合物及其医药用途
PCT/CN2021/101870 WO2022052564A1 (zh) 2019-12-20 2021-06-23 乏氧活化的dna烷化剂及其医药用途

Publications (1)

Publication Number Publication Date
KR20230065309A true KR20230065309A (ko) 2023-05-11

Family

ID=76477075

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237011813A Pending KR20230065309A (ko) 2019-12-20 2021-06-23 저산소증-활성화된 dna 알킬화제 및 그의 의학적 용도

Country Status (7)

Country Link
US (2) US20230026163A1 (https=)
EP (2) EP4079738A4 (https=)
JP (1) JP2023542286A (https=)
KR (1) KR20230065309A (https=)
CN (2) CN114466853B (https=)
TW (4) TWI837402B (https=)
WO (2) WO2021120717A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI837402B (zh) * 2019-12-20 2024-04-01 大陸商深圳艾欣達偉醫藥科技有限公司 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
EP4428138A4 (en) * 2021-11-05 2025-08-27 Ascentawits Pharmaceuticals Ltd AKR1C3-ACTIVATED DNA ALKYLATING AGENT AND ITS MEDICAL USE
CN114106042B (zh) * 2021-11-12 2022-09-16 深圳艾欣达伟医药科技有限公司 一种氘代化合物及其制备方法和应用
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
CN119233822A (zh) 2022-05-23 2024-12-31 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
CN115626938B (zh) * 2022-09-02 2026-04-17 温州医科大学 一种化合物rx4及其在抗结肠癌药物中的作用
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
KR20260009356A (ko) * 2023-05-11 2026-01-19 아센타위츠 파마슈티컬즈 리미티드 주사액 제제 및 이의 제조 방법, 및 상용성 약액 및 이의 제조 방법
WO2025026214A1 (zh) 2023-07-28 2025-02-06 深圳艾欣达伟医药科技有限公司 治疗p53基因突变或缺陷阴性癌症、肿瘤患者

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617398A (en) * 1982-04-12 1986-10-14 The Research Foundation Of State University Of New York Phosphoaziridine compounds useful for treatment of tumors
AU5935600A (en) * 1999-07-14 2001-01-30 Richard F. Borch Phosphoramide compounds
WO2004062596A2 (en) * 2003-01-09 2004-07-29 Zeneus Pharma Limited Antineoplastic ether lipid compounds having a four carbon backbone
AU2005325676A1 (en) * 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
CA2592118C (en) * 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
CN1948311A (zh) * 2006-11-09 2007-04-18 上海交通大学 2－碘代苯基－6－三氟甲基咪唑并[1,2－a]吡啶－3－乙酰胺类化合物及制备方法
US9278904B2 (en) * 2013-12-31 2016-03-08 Chemapotheca, Llc Synthesis of chiral amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds
CN104098432B (zh) * 2014-06-30 2016-03-30 福建师范大学福清分校 一种三氟甲基化芳烃的合成方法
TWI674258B (zh) * 2015-03-10 2019-10-11 大陸商深圳艾欣達偉醫藥科技有限公司 Ｄｎａ烷化劑
JP7327900B2 (ja) * 2015-06-24 2023-08-16 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド アジリジン含有ｄｎａアルキル化剤
EP3390415B1 (en) * 2015-11-16 2020-02-26 Obi Pharma, Inc. (r)- and (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation
CN106279321A (zh) 2016-08-09 2017-01-04 南京医科大学 吉西他滨ProTide乏氧活化前药及其应用
CN107118231B (zh) * 2017-03-17 2019-06-07 北京大学 萘醌磷酰胺类化合物及其在作为细胞铁死亡诱导剂中的用途
WO2018184003A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
CN107513057A (zh) 2017-09-06 2017-12-26 南京医科大学 一类乐伐替尼的乏氧活化前药及其应用
TW201919644A (zh) * 2017-09-29 2019-06-01 台灣浩鼎生技股份有限公司 治療血癌的方法
WO2020022868A1 (ko) * 2018-07-27 2020-01-30 에스케이이노베이션 주식회사 입자 균일도가 우수한 모데나이트 제올라이트 및 그 제조방법
TWI837402B (zh) * 2019-12-20 2024-04-01 大陸商深圳艾欣達偉醫藥科技有限公司 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途

Also Published As

Publication number Publication date
TWI837402B (zh) 2024-04-01
WO2022052564A1 (zh) 2022-03-17
CN115667278A (zh) 2023-01-31
TW202128188A (zh) 2021-08-01
TW202210083A (zh) 2022-03-16
WO2021120717A1 (zh) 2021-06-24
TW202421161A (zh) 2024-06-01
EP4079738A4 (en) 2024-04-24
TW202135831A (zh) 2021-10-01
CN114466853A (zh) 2022-05-10
JP2023542286A (ja) 2023-10-06
CN114466853B (zh) 2026-04-14
US20230026163A1 (en) 2023-01-26
EP4079738A1 (en) 2022-10-26
US20230339991A1 (en) 2023-10-26
TWI833055B (zh) 2024-02-21
TWI893202B (zh) 2025-08-11
EP4212538A1 (en) 2023-07-19
EP4212538A4 (en) 2024-11-13

Similar Documents

Publication Publication Date Title
TWI893202B (zh) 缺氧活化的dna烷化劑及其醫藥用途
Duan et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs
Xi et al. Long-circulating amphiphilic doxorubicin for tumor mitochondria-specific targeting
TW201728583A (zh) 氨基噻唑化合物及其用途
CN111971070A (zh) Hsp90-靶向缀合物及其制剂
Banerjee et al. X-ray crystallography-guided design, antitumor efficacy, and QSAR analysis of metabolically stable cyclopenta-pyrimidinyl dihydroquinoxalinone as a potent tubulin polymerization inhibitor
TW202320804A (zh) Akr1c3活化的dna烷化劑及其醫藥用途
AU2017207299A1 (en) Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)
CA3116234A1 (en) Combination therapy utilizing dna alkylating agents and atr inhibitors
EP4494643A1 (en) Method for treating patient with brca-mutated cancer
AU2022263701A1 (en) Use of medicament in treatment of tumor disease
CN111481551A (zh) 肿瘤选择性联合疗法
US20230226198A1 (en) Artemisinin Derivatives
CN107108632B (zh) 作为激酶调节剂的氘化的三唑并哒嗪
TW202348235A (zh) 吉西他濱抗癌衍生物及抗癌醫藥用途
Nie et al. Synthesis of novel deuterated EGFR/ALK dual-target inhibitors and their activity against non-small cell lung cancer
KR102055176B1 (ko) 암 치료용 키나제 저해제
TW201249453A (en) Berberine-containing pharmaceutical composition for inhibiting cancer stem cells growth or carcinoma metastasis and application thereof
EP4495121A1 (en) Camptothecin derivatives that bind to ddx5 protein and prodrugs thereof
TWI769470B (zh) 用於治療疾病的fak抑制劑和btk抑制劑的組合
KR102142164B1 (ko) 퀴논 화합물 및 암의 치료를 위한 그것의 용도
TW202340152A (zh) 用於靶向療法之複合體
Pashaei et al. Anthracycline Drugs: An Update on Chemistry, Structure-Activity Relationship, Mechanism of Action, Cardiotoxicity, Physicochemical and Pharmacokinetic Properties
KR20240171143A (ko) 표적 치료를 위한 접합체
HK40128848A (zh) 用於治疗癌症的化合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902